Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ

U. E. Studer, G. Casanova, R. Kraft, E. J. Zingg, D. L. Lamm, M. S. Soloway

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Ten pyeloureteral systems in 8 patients (mean age 74 years) with cytologically proved ureteral carcinoma in situ (1 combined with ureteral papillary tumors) were perfused with bacillus Calmette-Guerin via a percutaneous nephrostomy tube. In 4 patients cytology results remained negative after 1 treatment course during an observation time of 18 to 28 months. In 1 patient a papillary tumor persisted with cytology results became negative for carcinoma in situ. Two patients with bilateral disease had repeated perfusion of bacillus Calmette-Guerin until cytology results became negative and they remained negative during observation for 18 months in 1. The other patient had a multifocal recurrence of carcinoma in situ, combined with a stage T1, grade 3 urothelial cancer in the bladder after 12 months and a recurrence of carcinoma in situ in 1 ureter after 24 months. In 1 patient treatment was stopped prematurely after severe septicemia. Although our short-term results are promising, percutaneous perfusion of bacillus Calmette-Guerin for carcinoma in situ of the upper urinary tract should be considered as an investigational treatment modality until long-term results are available.

Original languageEnglish
Pages (from-to)975-977
Number of pages3
JournalJournal of Urology
Volume142
Issue number4
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Carcinoma in Situ
Mycobacterium bovis
Urinary Tract
Perfusion
Cell Biology
Observation
Recurrence
Percutaneous Nephrostomy
Investigational Therapies
Ureter
Urinary Bladder Neoplasms
Neoplasms
Sepsis
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Studer, U. E., Casanova, G., Kraft, R., Zingg, E. J., Lamm, D. L., & Soloway, M. S. (1989). Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. Journal of Urology, 142(4), 975-977.

Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. / Studer, U. E.; Casanova, G.; Kraft, R.; Zingg, E. J.; Lamm, D. L.; Soloway, M. S.

In: Journal of Urology, Vol. 142, No. 4, 01.01.1989, p. 975-977.

Research output: Contribution to journalArticle

Studer, UE, Casanova, G, Kraft, R, Zingg, EJ, Lamm, DL & Soloway, MS 1989, 'Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ', Journal of Urology, vol. 142, no. 4, pp. 975-977.
Studer UE, Casanova G, Kraft R, Zingg EJ, Lamm DL, Soloway MS. Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. Journal of Urology. 1989 Jan 1;142(4):975-977.
Studer, U. E. ; Casanova, G. ; Kraft, R. ; Zingg, E. J. ; Lamm, D. L. ; Soloway, M. S. / Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. In: Journal of Urology. 1989 ; Vol. 142, No. 4. pp. 975-977.
@article{0dbfd0471a194a5abdb5d3463f4f2bff,
title = "Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ",
abstract = "Ten pyeloureteral systems in 8 patients (mean age 74 years) with cytologically proved ureteral carcinoma in situ (1 combined with ureteral papillary tumors) were perfused with bacillus Calmette-Guerin via a percutaneous nephrostomy tube. In 4 patients cytology results remained negative after 1 treatment course during an observation time of 18 to 28 months. In 1 patient a papillary tumor persisted with cytology results became negative for carcinoma in situ. Two patients with bilateral disease had repeated perfusion of bacillus Calmette-Guerin until cytology results became negative and they remained negative during observation for 18 months in 1. The other patient had a multifocal recurrence of carcinoma in situ, combined with a stage T1, grade 3 urothelial cancer in the bladder after 12 months and a recurrence of carcinoma in situ in 1 ureter after 24 months. In 1 patient treatment was stopped prematurely after severe septicemia. Although our short-term results are promising, percutaneous perfusion of bacillus Calmette-Guerin for carcinoma in situ of the upper urinary tract should be considered as an investigational treatment modality until long-term results are available.",
author = "Studer, {U. E.} and G. Casanova and R. Kraft and Zingg, {E. J.} and Lamm, {D. L.} and Soloway, {M. S.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "142",
pages = "975--977",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ

AU - Studer, U. E.

AU - Casanova, G.

AU - Kraft, R.

AU - Zingg, E. J.

AU - Lamm, D. L.

AU - Soloway, M. S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Ten pyeloureteral systems in 8 patients (mean age 74 years) with cytologically proved ureteral carcinoma in situ (1 combined with ureteral papillary tumors) were perfused with bacillus Calmette-Guerin via a percutaneous nephrostomy tube. In 4 patients cytology results remained negative after 1 treatment course during an observation time of 18 to 28 months. In 1 patient a papillary tumor persisted with cytology results became negative for carcinoma in situ. Two patients with bilateral disease had repeated perfusion of bacillus Calmette-Guerin until cytology results became negative and they remained negative during observation for 18 months in 1. The other patient had a multifocal recurrence of carcinoma in situ, combined with a stage T1, grade 3 urothelial cancer in the bladder after 12 months and a recurrence of carcinoma in situ in 1 ureter after 24 months. In 1 patient treatment was stopped prematurely after severe septicemia. Although our short-term results are promising, percutaneous perfusion of bacillus Calmette-Guerin for carcinoma in situ of the upper urinary tract should be considered as an investigational treatment modality until long-term results are available.

AB - Ten pyeloureteral systems in 8 patients (mean age 74 years) with cytologically proved ureteral carcinoma in situ (1 combined with ureteral papillary tumors) were perfused with bacillus Calmette-Guerin via a percutaneous nephrostomy tube. In 4 patients cytology results remained negative after 1 treatment course during an observation time of 18 to 28 months. In 1 patient a papillary tumor persisted with cytology results became negative for carcinoma in situ. Two patients with bilateral disease had repeated perfusion of bacillus Calmette-Guerin until cytology results became negative and they remained negative during observation for 18 months in 1. The other patient had a multifocal recurrence of carcinoma in situ, combined with a stage T1, grade 3 urothelial cancer in the bladder after 12 months and a recurrence of carcinoma in situ in 1 ureter after 24 months. In 1 patient treatment was stopped prematurely after severe septicemia. Although our short-term results are promising, percutaneous perfusion of bacillus Calmette-Guerin for carcinoma in situ of the upper urinary tract should be considered as an investigational treatment modality until long-term results are available.

UR - http://www.scopus.com/inward/record.url?scp=0024442561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024442561&partnerID=8YFLogxK

M3 - Article

VL - 142

SP - 975

EP - 977

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -